Etoposide for the treatment of paediatric tumours: What is the best way to give it?

European Journal of Cancer Part A

Volumn 32, Issue 13, 1996, Pages 2291-2297

  Lowis, S P ^a   Newell, D R ^b  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Etoposide; Paediatric oncology; Pharmacodynamics; Pharmacokinetics; Schedule dependency

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOFOS; ETOPOSIDE; PRODRUG;

ANEMIA; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PEDIATRICS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; NEOPLASMS;

EID: 0030462907     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00301-2     Document Type: Review

References (65)

1. 1. Drewinko B, Barlogie B. Survival and cell cycle progression delay of human lymphoma cells in vitro exposed to VP 16-213, Cancer Treat Rep 1976, 60, 1295-1306.
2. 2. D'Incalci M, Erba E, Vaghi M, Morasca L. In vitro cytotoxicity of VP16 on primary tumour and metastasis of Lewis lung carcinoma. Eur J Cancer 1982, 18, 377-380.
3. 3. Matsushima Y, Kanzawa F, Hoshi A, et al. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985, 14, 104-107.
4. 4. Roed H, Vindelov LL, Christensen IJ, et al. The effect of the two epipodophyllotoxin derivatives etoposide (VP16) and teniposide (VM26) on cell lines established from patients with small cell carcinoma of the lung. Cancer Chemother Pharmacol 1987, 19, 16-20.
5. 5. Wolff SN, Grosh WW, Prater K, Hande KR. In vitro pharmacodynamic evaluation of VP 16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 1987, 19, 246-249.
6. 6. Lowis SP, Newell DR, Pearson ADJ. Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro. Eur J Cancer 1995, 31A, 622-626.
7. 7. Ohishi Y, Fujiwara K, Kohno I. Effect of the exposure dose of etoposide on the cell growth and cell kinetics of human ovarian cancer cells. Cancer Chemother Pharmacol 1996, 38, 141-146.
8. 8. Dombernowsky P, Nissen NI. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Path Microbiol Scand A 1973, 81, 715-724.
9. 9. Cavalli F, Sonntag RW, Jungi F, Senn HJ, Brunner KW. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosing schedules. Cancer Treat Rep 1978, 62, 473-475.
10. 10. Mead GM, Thompson J, Sweetenham JW, Buchanan RB, Whitehouse JMA, Williams CJ. Extensive stage small cell carcinoma of the bronchus. A randomized study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide. Cancer Chemother Pharmacol 1987, 19, 172-174.
11. 11. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evauate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989, 7, 1333-1340.
12. 12. Clark PI, Slevin ML, Joel SP, et al. A randomized trial of two etoposide schedules in small cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994, 12, 1427-1435.
13. 13. Clark PI, Cottier B, Joel SP, Slevin ML. Two prolonged schedules of single agent oral etoposide of differing duration and dose in patients with untreated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1991, 10, 268 (abstract).
14. 14. Abratt RP, Willcox PA, de Groot M, et al. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung cancer. Eur J Cancer 1991, 27, 28-30.
15. 15. Chatelut E, Chevreau C, Blancy E, et al. Pharmacokinetic and toxicity of two modalities of etoposide infusion in metastatic non-small cell lung carcinoma. Cancer Chemother Pharmcol 1990, 26, 365-368.
16. 16. Goldberg RM, Jett JR, Therneau TM, et al. Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment Group. J Natl Cancer Inst 1990, 82, 1899-1903.
17. 17. Schell FC, Yap HY, Issell B, Esparza L. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol 1982, 7, 223-225.
18. 18. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. Cancer 1994, 73, 2824-2831.
19. 19. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA. Prolonged administration of low dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol 1993, 11, 1322-1328.
20. 20. Carney DN, Grogan L, Smit EF, et al. Single agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1990, 17(Suppl. 2), 49-53.
21. 21. Clark PI, Cottier B. The activity of 10-14-and 21-day schedules of single agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 1992, 19(Suppl. 14), 36-39.
22. 22. Sessa C, Zucchetti M, Torri V, et al. Chronic oral etoposide in small cell lung cancer: clinical and pharmacokinetic results, Annals Oncol 1993, 4, 553-558.
23. 23. Johnson PWM, Seymour MT, Waines A, Squires L, Slevin ML. Etoposide as a single agent in small cell lung cancer (SCLC): as good as combination chemotherapy? Proc Am Soc Clin Oncol 1992, 11, 291 (abstract).
24. 24. Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA. Single agent chemotherapy trials in small cell lung cancer, 1970-1990. The case for studies in previously treated patients. J Clin Oncol 1992, 10, 484-498.
25. 25. Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP16 in refractory small cell lung cancer: a Hoosier Oncology Group Study. Semin Oncol 1990, 17(Suppl. 2), 32-35.
26. 26. Miller AA, Herndon II J, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995, 13, 1871-1879.
27. 27. Hainsworth JD, Greco FA. Etoposide: twenty years later. Annals Oncol 1995, 6, 325-341.
28. 28. Campbell LA, Seeger RC, Harris RE, Villabianca JG, Matthay KK. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 1993, 11, 623-629.
29. 29. Meresse V, Vassal G, Michon J, et al. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1993, 11, 630-637.
30. 30. Davidson A, Lewis I, Pearson ADJ, Stevens MCG, Pinkerton CR. 21-day schedule oral etoposide in children - a feasibility study. Eur J Cancer 1993, 29A, 2223-2225.
31. 31. Mathew P, Ribeiro RC, Sonnichsen D, et al. Phase I study of oral etoposide in children with refractory solid tumours. J Clin Oncol 1994, 12, 1452-1457.
32. 32. Mahmoud H, Relling M, Crist W, Rivera G, et al. Effective retrieval therapy including daily oral etoposide for children with relapsed acute lymphoblastic leukemia. Med Pediatr Oncol 1993, 21, 555.
33. 33. Maksymiuk AW, Jett JR, Earle JD, et al. Sequencing and schedule dependent effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 1994, 12, 70-76.
34. 34. Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide phrmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharm Ther 1994, 56, 503-511.
35. 35. Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994, 12, 2390-2397.
36. 36. Brindley CJ, Antoniw P, Newlands ES, Bagshawe KD. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP16-213) in patients with gestational choriocarcinoma and malignant teratoma. Cancer Chemother Pharmacol 1985, 15, 66-71.
37. 37. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase I clinical and pharmacological study of 72 hr continuous infusion of etoposide in patients with advanced cancer. Cancer Res 1987, 47, 1952-1956.
38. 38. Desoize B, Marechal F, Cattan A. Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. Br J Cancer 1990, 62, 840-841.
39. 39. Miller AA, Stewart CF, Tollet EA. Clinical pharmacodynamics of continuous infusion etoposide. Cancer Chemother Pharmacol 1990, 25, 361-366.
40. 40. Mick R, Ratain MJ. Modelling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 1991, 83, 1560-1564.
41. 41. Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of systemic exposure to unbound etoposide and haematologic toxicity. Clin Pharm Ther 1991, 50, 385-393.
42. 42. Miller AA, Tolley EA, Niell HB, Stewart CF, Griffin JP. Pharmacodynamics of three daily infusion of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 1992, 31, 161-166.
43. 43. Minami H, Shimokata K, Saka H, et al. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 1993, 11, 1602-1608.
44. 44. Millward MJ, Newell DR, Yuen K, et al. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with breast cancer. Cancer Chemother Pharmacol 1995, 37, 161-167.
45. 45. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996, 14, 257-267.
46. 46. D'Incalci M, Farina P, Sessa C, et al. Pharmacokinetic of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 1982, 7, 141-145.
47. 47. Evans WE, Sinkule JA, Crom WR, et al. Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 1982, 7, 147-150.
48. 48. Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans WE. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumours. Cancer Res 1984, 44, 3109-3113.
49. 49. Lowis SP, Pearson ADJ, Newell DR, Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 1993, 53, 4881-4889.
50. 50. Boos J, Krumpelmann S, Schulze-Westhoff P, et al. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age dependent dose calculation? J Clin Oncol 1995, 13, 2954-2960.
51. 51. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 1991, 9, 1480-1486.
52. 52. Rodman JH, Sunderland M, Kavanagh RL, et al. Pharmacokinetics of continuous infusion methotrexate and teniposide in paediatric cancer patients. Cancer Res 1990, 50, 4267-4271.
53. 53. Rodman JH, Abromowitch M, Sinkule JA, et al. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1981, 7, 1007-1014.
54. 54. Stromgren AS, Sorensen BT, Jakobsen P, Jakobsen A. A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 1993, 32, 226-230.
55. 55. Gentili D, Zucchetti M, Torri V, Sessa C, et al. A limited sampling model for the Pharmacokinetics of etoposide given orally. Cancer Chemother Pharmacol 1993, 32, 482-486.
56. 56. Joel SP, Heap L, Robbins S, Clarke PI, Slevin ML. A limited sampling strategy for the calculation of etoposide pharmacokinetics. Proc Am Soc Clin Oncol 1990, 9, 260.
57. 57. Joel SP, Dolega-Ossowski E, Jones K, et al. The bioavailability of oral etoposide during prolonged administration and the development of a limited sampling strategy for the estimation of AUC after an oral dose. Proc Am Assoc Cancer Res 1991, 32, 178.
58. 58. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of drug resistance. Cancer 1993, 72, 3302-3314.
59. 59. Cowie F, Pinkerton CR, Dick G. Continuous infusion of cyclosporin A to reverse etoposide resistance in pediatric tumours. Anti-Cancer Drugs 1994, 5(Suppl. 1), 65.
60. 60. Cowie FJ, Pinkerton CR, Philips M, et al. Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 1995, 71, 877-881.
61. 61. Schacter LP, Igwemezie LN, Seyedsadr M, et al. Clinical and pharmacokinetic overview of parenteral etoposide phosphate. Cancer Chemother Pharmacol 1994, 34(Suppl.), S58-S63.
62. 62. Budman DR, Igwemezie LM, Kaul S, et al. Phase I evaluation of a water soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumours. J Clin Oncol 1994, 12, 1902-1909.
63. 63. Hainsworth JD, Levitan N, Wampler GL, et al. Phase II randomised study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J Clin Oncol 1995,13, 1436-1442.
64. 64. Kaul S, Igwemezie LM, Stewart DJ, et al. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumours. J Clin Oncol 1995, 13, 2835-2841.
65. 65. Millward MJ, Newell DR, Mummaneni V, et al. Phase I and pharmacokinetic study of a water soluble etoposide prodrug, etoposide phosphate (BMY-40481). Eur J Cancer 1995, 31A, 2409-2411.